William Blair Issues Pessimistic Outlook for Incyte Earnings

Incyte Corporation (NASDAQ:INCY) – Investment analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for shares of Incyte in a note issued to investors on Monday, July 14th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $1.06 per share for the quarter, down from their previous forecast of $1.11. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s FY2025 earnings at $4.55 EPS and FY2026 earnings at $5.75 EPS.

A number of other analysts have also recently issued reports on the company. Morgan Stanley decreased their target price on Incyte from $69.00 to $65.00 and set an “equal weight” rating for the company in a research report on Monday, March 24th. Wells Fargo & Company increased their price objective on Incyte from $58.00 to $59.00 and gave the company an “equal weight” rating in a report on Wednesday, April 30th. JPMorgan Chase & Co. cut their target price on shares of Incyte from $68.00 to $67.00 and set a “neutral” rating on the stock in a report on Monday. Wall Street Zen upgraded shares of Incyte from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 30th. Finally, Royal Bank Of Canada set a $67.00 price objective on shares of Incyte and gave the stock a “sector perform” rating in a research report on Monday, June 23rd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $74.47.

Incyte Price Performance

INCY stock opened at $68.25 on Tuesday. The business has a 50 day moving average price of $66.56 and a 200 day moving average price of $66.63. The company has a quick ratio of 2.00, a current ratio of 2.04 and a debt-to-equity ratio of 0.01. The stock has a market cap of $13.21 billion, a price-to-earnings ratio of 213.29, a PEG ratio of 0.59 and a beta of 0.68. Incyte has a fifty-two week low of $53.56 and a fifty-two week high of $83.95.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.15. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $996.17 million. Incyte had a return on equity of 2.77% and a net margin of 0.48%. Incyte’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.64 earnings per share.

Insider Transactions at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 10,903 shares of the firm’s stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the company’s stock, valued at $2,708,553.60. This trade represents a 21.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $68.61, for a total transaction of $41,097.39. Following the completion of the sale, the executive vice president directly owned 26,504 shares of the company’s stock, valued at $1,818,439.44. The trade was a 2.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,119 shares of company stock valued at $1,371,385 over the last three months. 17.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Proficio Capital Partners LLC acquired a new position in shares of Incyte in the 4th quarter valued at about $3,549,000. Raymond James Financial Inc. acquired a new position in Incyte during the 4th quarter worth approximately $3,623,000. Sequoia Financial Advisors LLC boosted its stake in shares of Incyte by 8.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 4,922 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 395 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Incyte by 161.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,275 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 787 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Incyte by 5.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 7,880 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 380 shares in the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.